id stringlengths 24 24 | title stringclasses 442
values | context stringlengths 151 3.71k | question stringlengths 12 270 | answers dict |
|---|---|---|---|---|
5ad3a053604f3c001a3fe996 | Pharmaceutical_industry | In the UK, the Medicines and Healthcare Products Regulatory Agency approves drugs for use, though the evaluation is done by the European Medicines Agency, an agency of the European Union based in London. Normally an approval in the UK and other European countries comes later than one in the USA. Then it is the National Institute for Health and Care Excellence (NICE), for England and Wales, who decides if and how the National Health Service (NHS) will allow (in the sense of paying for) their use. The British National Formulary is the core guide for pharmacists and clinicians. | Who is responsible for approving drugs in the NHS? | {
"answer_start": [],
"text": []
} |
5ad3a053604f3c001a3fe997 | Pharmaceutical_industry | In the UK, the Medicines and Healthcare Products Regulatory Agency approves drugs for use, though the evaluation is done by the European Medicines Agency, an agency of the European Union based in London. Normally an approval in the UK and other European countries comes later than one in the USA. Then it is the National Institute for Health and Care Excellence (NICE), for England and Wales, who decides if and how the National Health Service (NHS) will allow (in the sense of paying for) their use. The British National Formulary is the core guide for pharmacists and clinicians. | After an approval in the UK, when does an approval occur in the NHS and other countries? | {
"answer_start": [],
"text": []
} |
5ad3a053604f3c001a3fe998 | Pharmaceutical_industry | In the UK, the Medicines and Healthcare Products Regulatory Agency approves drugs for use, though the evaluation is done by the European Medicines Agency, an agency of the European Union based in London. Normally an approval in the UK and other European countries comes later than one in the USA. Then it is the National Institute for Health and Care Excellence (NICE), for England and Wales, who decides if and how the National Health Service (NHS) will allow (in the sense of paying for) their use. The British National Formulary is the core guide for pharmacists and clinicians. | Who decides how the USA will allow drugs? | {
"answer_start": [],
"text": []
} |
5ad3a053604f3c001a3fe999 | Pharmaceutical_industry | In the UK, the Medicines and Healthcare Products Regulatory Agency approves drugs for use, though the evaluation is done by the European Medicines Agency, an agency of the European Union based in London. Normally an approval in the UK and other European countries comes later than one in the USA. Then it is the National Institute for Health and Care Excellence (NICE), for England and Wales, who decides if and how the National Health Service (NHS) will allow (in the sense of paying for) their use. The British National Formulary is the core guide for pharmacists and clinicians. | Who does the evaluations for drugs in the United States? | {
"answer_start": [],
"text": []
} |
571af9329499d21900609bc5 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | What is subject to the Orphan Drug Act? | {
"answer_start": [
129
],
"text": [
"diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances"
]
} |
571af9329499d21900609bc6 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | What is given to companies who develop drugs for "orphan diseases"? | {
"answer_start": [
426
],
"text": [
"tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents"
]
} |
571af9329499d21900609bc7 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | Why are these companies rewarded? | {
"answer_start": [
282
],
"text": [
"Because medical research and development of drugs to treat such diseases is financially disadvantageous"
]
} |
571d2b4ddd7acb1400e4c234 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | What is a term for rare diseases in some territories? | {
"answer_start": [
52
],
"text": [
"orphan diseases"
]
} |
571d2b4ddd7acb1400e4c235 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | What size of disease populations are subject to the Orphan Drug Act? | {
"answer_start": [
148
],
"text": [
"fewer than 200,000 patients"
]
} |
571d2b4ddd7acb1400e4c236 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | What is one financial benefit to researching orphan drugs? | {
"answer_start": [
426
],
"text": [
"tax reductions"
]
} |
571d2b4ddd7acb1400e4c237 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | What is the length of time of market exclusivity of an orphan drug? | {
"answer_start": [
511
],
"text": [
"seven years"
]
} |
5ad3a4c6604f3c001a3fea95 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | What is subject to patients in the United States? | {
"answer_start": [],
"text": []
} |
5ad3a4c6604f3c001a3fea96 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | What is given to companies who develop rules for "orphan diseases"? | {
"answer_start": [],
"text": []
} |
5ad3a4c6604f3c001a3fea97 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | Why are these rules rewarded? | {
"answer_start": [],
"text": []
} |
5ad3a4c6604f3c001a3fea98 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | What is a term for rare rules in some territories? | {
"answer_start": [],
"text": []
} |
5ad3a4c6604f3c001a3fea99 | Pharmaceutical_industry | There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents. | What size of disease populations are subject to patents? | {
"answer_start": [],
"text": []
} |
571af9889499d21900609bcb | Pharmaceutical_industry | Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective. | Who argued against regulators? | {
"answer_start": [
0
],
"text": [
"Ben Goldacre"
]
} |
571d3ae3dd7acb1400e4c25c | Pharmaceutical_industry | Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective. | Who argued that drug regulators were greater serving the interests of the drug companies than the patients? | {
"answer_start": [
0
],
"text": [
"Ben Goldacre"
]
} |
571d3ae3dd7acb1400e4c25d | Pharmaceutical_industry | Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective. | The business friendships between which parties have been criticized? | {
"answer_start": [
389
],
"text": [
"regulator and company employees"
]
} |
571d3ae3dd7acb1400e4c25e | Pharmaceutical_industry | Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective. | Goldacre argued that which party didn't require that new drugs be improved at all? | {
"answer_start": [
437
],
"text": [
"regulators"
]
} |
5ad3ad2f604f3c001a3febe5 | Pharmaceutical_industry | Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective. | Who argued against the public? | {
"answer_start": [],
"text": []
} |
5ad3ad2f604f3c001a3febe6 | Pharmaceutical_industry | Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective. | Who argued that drug regulators were greater serving the interests of patients than the drug companies? | {
"answer_start": [],
"text": []
} |
5ad3ad2f604f3c001a3febe7 | Pharmaceutical_industry | Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective. | The business friendships between which parties have been praised? | {
"answer_start": [],
"text": []
} |
5ad3ad2f604f3c001a3febe8 | Pharmaceutical_industry | Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective. | The FDA argued that which party didn't require that new drugs be improved at all? | {
"answer_start": [],
"text": []
} |
5ad3ad2f604f3c001a3febe9 | Pharmaceutical_industry | Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective. | Who argues that regulators do not require that new regulators offer an improvement? | {
"answer_start": [],
"text": []
} |
571d2c3b5efbb31900334ec2 | Pharmaceutical_industry | In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society. | NICE decides the availability of drugs in which two countries? | {
"answer_start": [
263
],
"text": [
"England and Wales"
]
} |
571d2c3b5efbb31900334ec3 | Pharmaceutical_industry | In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society. | What is the name of the organization in Scotland that decides the availability of drugs? | {
"answer_start": [
429
],
"text": [
"Scottish Medicines Consortium"
]
} |
571d2c3b5efbb31900334ec4 | Pharmaceutical_industry | In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society. | What threshold must a drug pass before it is approved? | {
"answer_start": [
575
],
"text": [
"cost-effectiveness"
]
} |
5ad3a314604f3c001a3fea45 | Pharmaceutical_industry | In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society. | QALY decides the availability of drugs in which two countries? | {
"answer_start": [],
"text": []
} |
5ad3a314604f3c001a3fea46 | Pharmaceutical_industry | In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society. | What is the name of the organization in Wales that decides the availability of drugs? | {
"answer_start": [],
"text": []
} |
5ad3a314604f3c001a3fea47 | Pharmaceutical_industry | In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society. | What threshold must a Wales pass before it is approved? | {
"answer_start": [],
"text": []
} |
5ad3a314604f3c001a3fea48 | Pharmaceutical_industry | In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society. | Where does QALY decide whether decide in what circumstances drugs and technologies will be made available? | {
"answer_start": [],
"text": []
} |
5ad3a314604f3c001a3fea49 | Pharmaceutical_industry | In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society. | What must the NHS do in order to be approved? | {
"answer_start": [],
"text": []
} |
571d2ccfdd7acb1400e4c23c | Pharmaceutical_industry | The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. | How much money did the top ten bestselling drugs make in 2013? | {
"answer_start": [
47
],
"text": [
"$75.6 billion"
]
} |
571d2ccfdd7acb1400e4c23d | Pharmaceutical_industry | The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. | What was the name of the top-selling anti-inflammatory drug in 2013? | {
"answer_start": [
103
],
"text": [
"Humira"
]
} |
571d2ccfdd7acb1400e4c23e | Pharmaceutical_industry | The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. | What was the bestselling drug in history? | {
"answer_start": [
415
],
"text": [
"Lipitor"
]
} |
571d2ccfdd7acb1400e4c23f | Pharmaceutical_industry | The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. | How much money did Lipitor make before the patent expired? | {
"answer_start": [
465
],
"text": [
"$141 billion"
]
} |
571d2ccfdd7acb1400e4c240 | Pharmaceutical_industry | The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. | In what year did Pfizer's patent over Lipitor expire? | {
"answer_start": [
545
],
"text": [
"2011"
]
} |
5ad3a5d0604f3c001a3feaa9 | Pharmaceutical_industry | The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. | How much money did the top ten bestselling drugs make in 2011? | {
"answer_start": [],
"text": []
} |
5ad3a5d0604f3c001a3feaaa | Pharmaceutical_industry | The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. | What was the name of the top-selling anti-inflammatory drug in 2011? | {
"answer_start": [],
"text": []
} |
5ad3a5d0604f3c001a3feaab | Pharmaceutical_industry | The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. | What was the bestselling drug in 2011? | {
"answer_start": [],
"text": []
} |
5ad3a5d0604f3c001a3feaac | Pharmaceutical_industry | The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. | How much money did Lipitor make after the patent expired? | {
"answer_start": [],
"text": []
} |
5ad3a5d0604f3c001a3feaad | Pharmaceutical_industry | The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. | In what year did Humira's patent over Lipitor expire? | {
"answer_start": [],
"text": []
} |
571d2dbf5efbb31900334ec8 | Pharmaceutical_industry | Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues. | How long do drug exclusivity rights usually last? | {
"answer_start": [
189
],
"text": [
"20 years"
]
} |
571d2dbf5efbb31900334ec9 | Pharmaceutical_industry | Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues. | Governments grant permission to market drugs after how many years? | {
"answer_start": [
259
],
"text": [
"10 to 15 years on average"
]
} |
571d2dbf5efbb31900334eca | Pharmaceutical_industry | Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues. | What enables a drug's owner to recover R&D costs? | {
"answer_start": [
378
],
"text": [
"Patent protection"
]
} |
571d2dbf5efbb31900334ecb | Pharmaceutical_industry | Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues. | What kind of drug is produced by competitors once a patent expires? | {
"answer_start": [
578
],
"text": [
"generic"
]
} |
571d2dbf5efbb31900334ecc | Pharmaceutical_industry | Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues. | What decade was the pharmaceutical industry's "golden era"? | {
"answer_start": [
1034
],
"text": [
"1990s"
]
} |
5ad3a6d2604f3c001a3feabf | Pharmaceutical_industry | Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues. | How long do company exclusivity rights usually last? | {
"answer_start": [],
"text": []
} |
5ad3a6d2604f3c001a3feac0 | Pharmaceutical_industry | Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues. | Governments grant permission to market companies after how many years? | {
"answer_start": [],
"text": []
} |
5ad3a6d2604f3c001a3feac1 | Pharmaceutical_industry | Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues. | What enables a drug's owner to recover patent costs? | {
"answer_start": [],
"text": []
} |
5ad3a6d2604f3c001a3feac2 | Pharmaceutical_industry | Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues. | What kind of drug is produced by competitors once an industry expires? | {
"answer_start": [],
"text": []
} |
5ad3a6d2604f3c001a3feac3 | Pharmaceutical_industry | Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues. | What decade was the pharmaceutical industry's "drug era"? | {
"answer_start": [],
"text": []
} |
571d2eafdd7acb1400e4c246 | Pharmaceutical_industry | In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. | The safety and efficacy of new drugs must be approved by what organization in the US? | {
"answer_start": [
74
],
"text": [
"Food and Drug Administration"
]
} |
571d2eafdd7acb1400e4c247 | Pharmaceutical_industry | In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. | What type of filing is used before beginning human trials? | {
"answer_start": [
192
],
"text": [
"Investigational New Drug"
]
} |
571d2eafdd7acb1400e4c248 | Pharmaceutical_industry | In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. | How many phases of human trials may be done after IND approval? | {
"answer_start": [
323
],
"text": [
"three"
]
} |
571d2eafdd7acb1400e4c249 | Pharmaceutical_industry | In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. | What type of application is filed after completing three phases of human trials? | {
"answer_start": [
667
],
"text": [
"New Drug Application"
]
} |
571d2eafdd7acb1400e4c24a | Pharmaceutical_industry | In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. | What type of risk assessment results in approving the drug to go on the market? | {
"answer_start": [
776
],
"text": [
"positive benefit-risk"
]
} |
5ad39f27604f3c001a3fe941 | Pharmaceutical_industry | In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. | What organization in the US must approve the safety and efficacy of testing? | {
"answer_start": [],
"text": []
} |
5ad39f27604f3c001a3fe942 | Pharmaceutical_industry | In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. | What type of filing is used before beginning risk assessment? | {
"answer_start": [],
"text": []
} |
5ad39f27604f3c001a3fe943 | Pharmaceutical_industry | In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. | How many phases of human trials may be done after review? | {
"answer_start": [],
"text": []
} |
5ad39f27604f3c001a3fe944 | Pharmaceutical_industry | In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. | What type of application is filed after completing three phases of products? | {
"answer_start": [],
"text": []
} |
5ad39f27604f3c001a3fe945 | Pharmaceutical_industry | In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. | What type of risk assessment results in approving the drug to go on to studies? | {
"answer_start": [],
"text": []
} |
571d2f3bdd7acb1400e4c250 | Pharmaceutical_industry | Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987. | "Drug reps" are usually hired by what type of firms? | {
"answer_start": [
191
],
"text": [
"Pharmaceutical companies"
]
} |
571d2f3bdd7acb1400e4c251 | Pharmaceutical_industry | Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987. | What law regulates drug marketing in the US? | {
"answer_start": [
563
],
"text": [
"Prescription Drug Marketing Act of 1987"
]
} |
571d2f3bdd7acb1400e4c252 | Pharmaceutical_industry | Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987. | Who do drug reps market to? | {
"answer_start": [
315
],
"text": [
"directly and personally to physicians"
]
} |
5ad3a829604f3c001a3feae7 | Pharmaceutical_industry | Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987. | "US reps" are usually hired by what type of firms? | {
"answer_start": [],
"text": []
} |
5ad3a829604f3c001a3feae8 | Pharmaceutical_industry | Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987. | What law regulates drug marketing in some countries? | {
"answer_start": [],
"text": []
} |
5ad3a829604f3c001a3feae9 | Pharmaceutical_industry | Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987. | Who do US reps market to? | {
"answer_start": [],
"text": []
} |
5ad3a829604f3c001a3feaea | Pharmaceutical_industry | Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987. | Who do US companies generally employ? | {
"answer_start": [],
"text": []
} |
5ad3a829604f3c001a3feaeb | Pharmaceutical_industry | Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987. | What is marketing of media in the US regulated by? | {
"answer_start": [],
"text": []
} |
571d34cadd7acb1400e4c256 | Pharmaceutical_industry | There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards. | Drug reps have been accused of giving what to health professionals? | {
"answer_start": [
251
],
"text": [
"'gifts' and biased information"
]
} |
571d34cadd7acb1400e4c257 | Pharmaceutical_industry | There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards. | Drug marketers have hired who as paid consultants? | {
"answer_start": [
661
],
"text": [
"physicians"
]
} |
571d34cadd7acb1400e4c258 | Pharmaceutical_industry | There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards. | What publications can drug ads be commonly found? | {
"answer_start": [
339
],
"text": [
"journals and conferences"
]
} |
5ad3aa82604f3c001a3feb45 | Pharmaceutical_industry | There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards. | What have drug reps been accused of giving to conferences? | {
"answer_start": [],
"text": []
} |
5ad3aa82604f3c001a3feb46 | Pharmaceutical_industry | There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards. | Conferences have hired who as paid consultants? | {
"answer_start": [],
"text": []
} |
5ad3aa82604f3c001a3feb47 | Pharmaceutical_industry | There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards. | What publications can advisory boards be commonly found in? | {
"answer_start": [],
"text": []
} |
5ad3aa82604f3c001a3feb48 | Pharmaceutical_industry | There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards. | Who has been accused of influencing consultants? | {
"answer_start": [],
"text": []
} |
5ad3aa82604f3c001a3feb49 | Pharmaceutical_industry | There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards. | What has stopped controversy? | {
"answer_start": [],
"text": []
} |
571a9f0e4faf5e1900b8ab3c | Umayyad_Caliphate | The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus. | In what year CE did the Second Muslim Civil War end? | {
"answer_start": [
139
],
"text": [
"692"
]
} |
571a9f0e4faf5e1900b8ab3d | Umayyad_Caliphate | The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus. | During what period did the Berber Revolt occur? | {
"answer_start": [
171
],
"text": [
"740–743 CE"
]
} |
571a9f0e4faf5e1900b8ab3e | Umayyad_Caliphate | The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus. | What branch took over Umayyad leadership during the Second Civil War? | {
"answer_start": [
297
],
"text": [
"Marwanid"
]
} |
5acf705877cf76001a684e2a | Umayyad_Caliphate | The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus. | What caused unrest in the provinces inside Syria? | {
"answer_start": [],
"text": []
} |
5acf705877cf76001a684e2b | Umayyad_Caliphate | The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus. | In what years did the First Muslim Civil War occur? | {
"answer_start": [],
"text": []
} |
5acf705877cf76001a684e2c | Umayyad_Caliphate | The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus. | When did leadership shift from the Marwanid branch to the Sufyanid branch? | {
"answer_start": [],
"text": []
} |
5acf705877cf76001a684e2d | Umayyad_Caliphate | The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus. | What year was the Caliphate of Cordoba started? | {
"answer_start": [],
"text": []
} |
5acf705877cf76001a684e2e | Umayyad_Caliphate | The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus. | What war strengthened the Umayyads? | {
"answer_start": [],
"text": []
} |
571a9f4010f8ca14003051c1 | Umayyad_Caliphate | Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus. | In what year was Ali killed? | {
"answer_start": [
24
],
"text": [
"661"
]
} |
571a9f4110f8ca14003051c2 | Umayyad_Caliphate | Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus. | Who killed Ali? | {
"answer_start": [
33
],
"text": [
"Kharijite partisan"
]
} |
571a9f4110f8ca14003051c3 | Umayyad_Caliphate | Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus. | Who made peace with Muawiyah I? | {
"answer_start": [
114
],
"text": [
"Hasan ibn Ali"
]
} |
571a9f4110f8ca14003051c4 | Umayyad_Caliphate | Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus. | Where was the capital of the Umayyad dynasty? | {
"answer_start": [
744
],
"text": [
"Damascus"
]
} |
5acf9c8b77cf76001a6854be | Umayyad_Caliphate | Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus. | When was a Kharijite partisan killed? | {
"answer_start": [],
"text": []
} |
5acf9c8b77cf76001a6854bf | Umayyad_Caliphate | Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus. | Who was the First Imam for the Shias? | {
"answer_start": [],
"text": []
} |
5acf9c8b77cf76001a6854c0 | Umayyad_Caliphate | Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus. | Who followed the conditions of the agreement? | {
"answer_start": [],
"text": []
} |
5acf9c8b77cf76001a6854c1 | Umayyad_Caliphate | Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus. | Who refused to hand over power to Muawiyah? | {
"answer_start": [],
"text": []
} |
5acf9c8b77cf76001a6854c2 | Umayyad_Caliphate | Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus. | Who was regarded as a fool? | {
"answer_start": [],
"text": []
} |
571a9f6a4faf5e1900b8ab42 | Umayyad_Caliphate | At the time, the Umayyad taxation and administrative practice were perceived as unjust by some Muslims. The Christian and Jewish population had still autonomy; their judicial matters were dealt with in accordance with their own laws and by their own religious heads or their appointees, although they did pay a poll tax for policing to the central state. Muhammad had stated explicitly during his lifetime that abrahamic religious groups (still a majority in times of the Umayyad Caliphate), should be allowed to practice their own religion, provided that they paid the jizya taxation. The welfare state of both the Muslim and the non-Muslim poor started by Umar ibn al Khattab had also continued. Muawiya's wife Maysum (Yazid's mother) was also a Christian. The relations between the Muslims and the Christians in the state were stable in this time. The Umayyads were involved in frequent battles with the Christian Byzantines without being concerned with protecting themselves in Syria, which had remained largely Christian like many other parts of the empire. Prominent positions were held by Christians, some of whom belonged to families that had served in Byzantine governments. The employment of Christians was part of a broader policy of religious assimilation that was necessitated by the presence of large Christian populations in the conquered provinces, as in Syria. This policy also boosted Muawiya's popularity and solidified Syria as his power base. | What form of tax were Christians required to pay? | {
"answer_start": [
570
],
"text": [
"jizya"
]
} |
571a9f6a4faf5e1900b8ab43 | Umayyad_Caliphate | At the time, the Umayyad taxation and administrative practice were perceived as unjust by some Muslims. The Christian and Jewish population had still autonomy; their judicial matters were dealt with in accordance with their own laws and by their own religious heads or their appointees, although they did pay a poll tax for policing to the central state. Muhammad had stated explicitly during his lifetime that abrahamic religious groups (still a majority in times of the Umayyad Caliphate), should be allowed to practice their own religion, provided that they paid the jizya taxation. The welfare state of both the Muslim and the non-Muslim poor started by Umar ibn al Khattab had also continued. Muawiya's wife Maysum (Yazid's mother) was also a Christian. The relations between the Muslims and the Christians in the state were stable in this time. The Umayyads were involved in frequent battles with the Christian Byzantines without being concerned with protecting themselves in Syria, which had remained largely Christian like many other parts of the empire. Prominent positions were held by Christians, some of whom belonged to families that had served in Byzantine governments. The employment of Christians was part of a broader policy of religious assimilation that was necessitated by the presence of large Christian populations in the conquered provinces, as in Syria. This policy also boosted Muawiya's popularity and solidified Syria as his power base. | Who was the mother of Yazid? | {
"answer_start": [
713
],
"text": [
"Maysum"
]
} |
571a9f6a4faf5e1900b8ab44 | Umayyad_Caliphate | At the time, the Umayyad taxation and administrative practice were perceived as unjust by some Muslims. The Christian and Jewish population had still autonomy; their judicial matters were dealt with in accordance with their own laws and by their own religious heads or their appointees, although they did pay a poll tax for policing to the central state. Muhammad had stated explicitly during his lifetime that abrahamic religious groups (still a majority in times of the Umayyad Caliphate), should be allowed to practice their own religion, provided that they paid the jizya taxation. The welfare state of both the Muslim and the non-Muslim poor started by Umar ibn al Khattab had also continued. Muawiya's wife Maysum (Yazid's mother) was also a Christian. The relations between the Muslims and the Christians in the state were stable in this time. The Umayyads were involved in frequent battles with the Christian Byzantines without being concerned with protecting themselves in Syria, which had remained largely Christian like many other parts of the empire. Prominent positions were held by Christians, some of whom belonged to families that had served in Byzantine governments. The employment of Christians was part of a broader policy of religious assimilation that was necessitated by the presence of large Christian populations in the conquered provinces, as in Syria. This policy also boosted Muawiya's popularity and solidified Syria as his power base. | What was Maysum's religion? | {
"answer_start": [
748
],
"text": [
"Christian"
]
} |
5acf6e1877cf76001a684e16 | Umayyad_Caliphate | At the time, the Umayyad taxation and administrative practice were perceived as unjust by some Muslims. The Christian and Jewish population had still autonomy; their judicial matters were dealt with in accordance with their own laws and by their own religious heads or their appointees, although they did pay a poll tax for policing to the central state. Muhammad had stated explicitly during his lifetime that abrahamic religious groups (still a majority in times of the Umayyad Caliphate), should be allowed to practice their own religion, provided that they paid the jizya taxation. The welfare state of both the Muslim and the non-Muslim poor started by Umar ibn al Khattab had also continued. Muawiya's wife Maysum (Yazid's mother) was also a Christian. The relations between the Muslims and the Christians in the state were stable in this time. The Umayyads were involved in frequent battles with the Christian Byzantines without being concerned with protecting themselves in Syria, which had remained largely Christian like many other parts of the empire. Prominent positions were held by Christians, some of whom belonged to families that had served in Byzantine governments. The employment of Christians was part of a broader policy of religious assimilation that was necessitated by the presence of large Christian populations in the conquered provinces, as in Syria. This policy also boosted Muawiya's popularity and solidified Syria as his power base. | What populations did not have autonomy? | {
"answer_start": [],
"text": []
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.